(Press-News.org) Recent advances have resulted in highly effective “tissue-agnostic” drugs that treat cancers based on their molecular markers rather than their tissue of origin, but very few of these drugs are approved for use in children. In an opinion paper publishing June 5 in the Cell Press journal Trends in Cancer, oncologists call for “ag(e)nostic” cancer treatments: drugs that are both tissue agnostic and approved for cancer patients of all ages.
“Cancer treatment in children is a huge unmet need. These drugs are extremely effective, and we want to see children have access to them,” says senior author Razelle Kurzrock, an oncologist at the Medical College of Wisconsin. “Personally, I think that all drugs should be age agnostic.”
In the past, cancers were diagnosed and treated based on their tissue of origin, but modern precision cancer treatments target specific molecular abnormalities either directly or by flagging them for the immune system. Since cancers from different tissues sometimes use the same molecular abnormalities to grow and evade the immune system, the same drugs can be used tissue-agnostically to treat various cancers. And because of their targeted nature, precision treatments often have fewer side effects compared to traditional cancer treatments.
“Cancer is driven by underlying genomic drivers; it’s not driven by whether the cancer comes from the colon or the breast,” says Kurzrock. “Precision treatments are like smart bombs—they give therapy that is precisely targeted to the abnormality in the cancer.”
However, very few tissue-agnostic precision drugs are approved for use in children. The researchers note that as of June 2024, 144 out of 187 precision cancer treatments were only FDA-approved for adults. Similar patterns are present in the European Union and Japan.
“Only three cancer drugs are approved across all ages,” says Kurzrock. “There are another four that are only approved for children in certain age groups, for example, age 12 and up or age 6 and up. But that still means that if you’re a 10-year-old and you have a tumor, insurance doesn’t have to pay for your drug if it’s only approved for use in 12-year-olds.”
The researchers say that there are several historical reasons why fewer precision treatments have been approved for children.
“By nature, children are defined as a more vulnerable population, and they can’t give their own consent,” says author Matthew Kudek, a pediatric oncologist at the Medical College of Wisconsin. “Another issue is that pediatric oncology doesn’t have the same potential for revenue generation as adult cancers do because childhood cancer as a whole is a rare thing, so each cancer inside of that is even rarer.”
However, from a scientific and clinical standpoint, the researchers argue that there’s no reason why these drugs shouldn’t be approved for children.
“Children actually tolerate drugs much better than adults, especially older adults,” says Kurzrock. “If you can treat an 80-year-old with a drug, you should be able to treat a 2-year-old. They’re much more adaptable and they experience much fewer side effects.”
Although the rarity of childhood cancer means that it is nearly impossible to find adequate patients to run pediatric clinical trials, the researchers say that these drugs could be approved for age-agnostic use by other means, for example, by analyzing electronic health record data.
“If we can understand a medicine’s absorption and clearance rates, and we know what dose might be needed to kill cancer cells, we can use those tools and data to make a compelling case that it is both safe and effective in different populations,” says Kudek. “Moving forward, age-agnostic approvals should be the norm for precision cancer treatments rather than an exception to the rule.”
###
This research was supported by the American Cancer Society, the MCW Cancer Center, the Pediatric Transplantation and Cellular Therapy Consortium, and Jeff Gordon Children’s Foundation.
Trends in Cancer, Kudek et al., “Ag(e)nostic precision oncology therapy approvals across the years” https://www.cell.com/trends/cancer/fulltext/S2405-8033(25)00111-6
Trends in Cancer (@trendscancer), published by Cell Press, is a monthly review journal that presents and debates the latest opportunities, impasses, and potential impacts of basic, translational, and clinical sciences but also discusses emergent relevant issues in pharma oncology R&D, technology and innovation, ethics and society, and current cancer policy and funding models. Learn more: http://www.cell.com/trends/cancer/home. To receive Cell Press media alerts, please contact press@cell.com.
END
Genetic ancestry is much more complicated than how people report their race and ethnicity. New research, using data from the National Institutes of Health’s (NIH) All of Us Research Program, finds that people who identify as being from the same race or ethnic group can have a wide range of genetic differences. The findings are reported June 5 in the Cell Press journal the American Journal of Human Genetics.
As doctors and researchers learn more about how genetic variants influence the incidence and course of human diseases, the study of genetic ancestry has become increasingly important. This research is driving the field of precision medicine, ...
Nematodes are the most abundant animal on earth, but when times get tough, these tiny worms have a hard time moving up and out. So, they play to the strength of their clade. If food runs out and competition turns fierce, they slither towards their numerous kin. They climb onto each other and over one another until their bodies forge a living tower that twists skyward where they might hitch a ride on a passing animal to greener and roomier pastures.
At least that’s what scientists assumed. For decades, these worm structures ...
CHICAGO --- A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology — boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist shortage, a large new study finds.
The findings will be published on Thursday (June 5) in JAMA Network Open.
“This is, to my knowledge, the first use of AI that demonstrably improves productivity, especially in health care. Even in other fields, I haven’t seen anything close to a 40% boost,” said senior author Dr. Mozziyar Etemadi, an assistant professor of anesthesiology ...
Areas of the brain that help a person differentiate between what is real and what is imaginary have been uncovered in a new study led by UCL researchers.
The research, published in Neuron, found that a region in the brain known as the fusiform gyrus – located behind one’s temples, on the underside of the brain’s temporal lobe – is involved in helping the brain to determine whether what we see is from the external world or generated by our imagination.
The researchers hope that their findings will increase understanding ...
About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident neovascular age-related macular degeneration development than among similar patients with diabetes who did not receive a GLP-1 RA. Further research is needed to elucidate the exact pathophysiological mechanisms involved and to understand the trade-offs between the benefits and risks of GLP-1 RAs.
Corresponding Author: To ...
About The Study: Among childhood cancer survivors in this cohort study, obesity was associated with an increased risk for multiple subsequent neoplasm types, while higher physical activity was associated with reduced subsequent neoplasm risk. Lifestyle interventions should be considered in future subsequent neoplasm prevention research.
Corresponding Author: To contact the corresponding author, Lenat Joffe, MD, MS, email ljoffe@northwell.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2025.1340)
Editor’s Note: Please see the article for additional ...
Chimpanzees (Pan troglodytes) can ‘catch’ yawns from an android imitating human facial expressions, according to new research from City St George’s, University of London.
The study, published in Scientific Reports, demonstrates that chimpanzees will both yawn and lie down in response to yawns made by an android, suggesting that it may act as a cue to rest rather than simply triggering an automatic response.
The findings appear to show contagious yawning due to an inanimate model for the first time, according to the authors, and the study also ...
At a prestigious award ceremony today in the University Aula in Bergen, Gayatri Chakravorty Spivak received the international research award from HRH Crown Prince Haakon of Norway. Spivak is University Professor in the Humanities at Columbia University.
The Holberg Prize is worth NOK 6 million (approx. USD 600,000) and is awarded annually for outstanding contributions to research in the humanities, social sciences, law or theology.
Expressing her deepest gratitude as well as her surprise on receiving the award, Spivak accepted the Holberg ...
To further accelerate its pioneering research in the field of quantum computing, the Fraunhofer Institute for Applied Solid State Physics IAF is expanding its unique quantum computing infrastructure with the latest system from Quantum Brilliance (QB).
Following a public tender, the Quantum Development Kit (QB-QDK2.0) is operational and integrated directly into the high-performance computing infrastructure at Fraunhofer IAF. The system requires no cryogenics, fits into a standard 19” server rack, and enables energy-efficient, hybrid quantum-classical computing in conventional IT environments. ...
Researchers at DZNE and the Department of Vascular Neurology at the University Hospital Bonn (UKB) aim to develop a computer model based on artificial intelligence (AI) to aid doctors in treating stroke patients. Serving as a digital assistance system, it is intended to predict the long-term outcome of patients after a minimally invasive treatment (mechanical thrombectomy) and potential complications, thereby helping doctors decide on the best possible therapy. A proof-of-concept study will now be undertaken to determine whether this is feasible using data from the “German Stroke Registry” and additional brain images. The project relies on an AI technology called “Swarm ...
